Reuters | |

NEW YORK/WASHINGTON (Reuters) - Well-timed trades in Gilead Sciences Inc’s (GILD.O) options ahead of good news on the biopharmaceutical company’s COVID-19 drug treatment may draw regulatory scrutiny, experts said.... | |

Market selloffs are fed by fear and are eventually exhausted when extreme pessimism is priced in and investments become re-anchored to the broader outlook for fundamentals.

CNBC | |

Robinhood’s outage comes after technical problems that began a week ago, when clients missed out on the biggest one-day point gain in the Dow in history.

Ronald Woessner | |

OTC companies face an inhospitable environment of illiquidity, toxic capital and no research coverage. | |

A merger of this type allows both organizations to attract investors across a spectrum of needs and provides new financial solutions as investors mature.

Ronald Woessner | |

Professors John Coffee and Joshua Mitts of Columbia, among others, would like short sellers to be more accountable to the public.

Frank Holmes | |

Low-to-negative rates make it challenging to generate income, and this may push investors into riskier assets.

Reuters | |

Morgan Stanley will get E*Trade’s more than 5.2 million client accounts and $360 billion of retail client assets as part of the deal

Harry Boxer | |

These four stocks have strong technical momentum that could carry them higher.

FXStreet | |

GBP/USD has been holding onto gains, weathering USD strength. Coronavirus headlines, Brexit speculation, and US data are among the factors moving.